Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2607-2615

  Luo, Xuemei ^a,b,d   Doherty, Jim ^c   Cappelleri, Joseph C ^d   Frush, Karen ^a,b  

^a DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d PFIZER INC   (United States)

Author keywords

Drug safety; Pediatrics; Pharmacoepidemiology; Study designs

Indexed keywords

METHYLPHENIDATE; QUINOLONE DERIVATIVE;

DRUG EXPOSURE; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; REVIEW;

CHILD; HUMANS; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY;

EID: 36349031164     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233250     Document Type: Review

References (39)

1. McPhillips HA, Stille CJ, Smith D, et al. Potential medication dosing errors in outpatient pediatrics. J Pediatr 2005;147:761-7
2. Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001;52:77-83
3. Chan KA, Hernandez-Diaz S. Pharmacoepidemiology and rheumatic disorders. Rheum Dis Clin North Am 2004;30:835-50,vii
4. Strom BL. What is pharmacoepidemiology? In: Strom BL, ed. Pharmacoepidemiology. Chichester, UK: Wiley, 2000
5. Luo X, Cappelleri JC, Frush K. A systematic review on the application of pharmacoepidemiology in assessing prescription drug-related adverse events in pediatrics. Curr Med Res Opin 2007;23:1015-24
6. Department of Health and Human Services. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Washington, DC: U.S. Government Printing Office, August, 1997
7. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283:1025-30
8. 't Jong GW, Vulto AG, de Hoog M, et al. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001;108:1089-93
9. Greenhill LL, Vitiello B, Abikoff H, et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry 2003;42:651-5
10. US Food and Drug Administration. The Pediatric Research Equity Act. Public Law 108-155. Available at http://www.fda.gov/cder/pediatric/S-650-PREA. pdf. Last access April 2007
11. Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety: surely we can do better. Clin Pharmacol Ther 2004;75:491-4
12. Roden DM. An underrecognized challenge in evaluating post-marketing drug safety. Circulation 2005;111:246-8
13. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003;5:833-41
14. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647-50
15. McKeever TM, Lewis SA, Smith C, et al. Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. J Allergy Clin Immunol 2002;109:43-50
16. van Staa TP, Bishop N, Leufkens HG, et al. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 2004;15:785-91
17. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003;111:97-109
18. Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339-48
19. Celedon JC, Litonjua AA, Ryan L, et al. Lack of association between antibiotic use in the first year of life and asthma, allergic rhinitis, or eczema at age 5 years. Am J Respir Crit Care Med 2002;166:72-5
20. Bremner SA, Carey IM, DeWilde S. Early-life exposure to antibacterials and the subsequent development of hayfever in childhood in the UK: case-control studies using the General Practice Research Database and the Doctors' Independent Network. Clin Exp Allergy 2003;33:1518-25
21. Johnson CC, Ownby DR, Alford SH, et al. Antibiotic exposure in early infancy and risk for childhood atopy. J Allergy Clin Immunol 2005;115:1218-24
22. Cullinan P, Harris J, Mills P, et al. Early prescriptions of antibiotics and the risk of allergic disease in adults: a cohort study. Thorax 2004;59:11-15
23. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005;15:764-76
24. Venn A, Bruinsma F, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004; 364:1513-18
25. Chalumeau M, Tonnelier S, D'Athis P, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics 2003;111:e714-19
26. Hallas J. Pharmacoepidemiology - current opportunities and challenges. Norwegian J Epidemiol 2001;11:7-12
27. Layton D, Key C, Shakir SA. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Pharmacoepidemiol Drug Saf 2003;12:31-40
28. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond 1995;29:41-9
29. Scott HD, Rosenbaum SE, Waters WJ, et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 1987;70:311-16
30. Hartzema AG, Porta M, Tilson HH. Pharmacoepidemiology, an Introduction, 3rd edn. Cincinnati, OH: Harvey Whitney Books Company, 1998:473-93
31. FDA Analysis of Cardiac Valvular Dysfunction with Use of Appetite Suppressants. http://www.fda.gov/cder/news/slides/index.htm. Last accessed: Aug 2006
32. Menniti-Ippolito F, Sagliocca L, Da Cas R, et al. Niflumic acid and cutaneous reactions in children. Arch Dis Child 2001;84:430-1
33. Sturkenboom M, Nicolosi A, Cantarutti L, et al. Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics 2005;116:e26-33
34. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81
35. Mann CJ. Observational research methods. Research design II: cohort, cross-sectional, and case-control studies. Emerg Med J 2003;20:54-60
36. Etminan M. Pharmacoepidemiology II: the nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004;24:1105-9
37. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics 2004;114:469-73
38. Colwell JA. Aspirin for the primary prevention of cardiovascular events. Drugs Today 2006;42:467-79
39. Hak E, Verheij TJ, Grobbee DE, et al. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health 2002;56:951-5. Review